Stocks

Indices

Learn

Home

Stocks

Q Line Biotech Ltd.

The current prices were last updated on 01 Jan.

Download App

Q Line Biotech Ltd.

Healthcare

Medical Equipment/Supplies/Accessories

NSE

BSE

Failed to fetch data.

Please reload or search another stock

Overview

Financials

Ratios

Peer Comparison

Shareholdings

Q-Line Biotech Overview

Today's Low

Today's High

Open

Prev. Close

P/E

Sector P/E

P/B

Sector P/B

Adj EPS

BVPS

OPM(%)

NPM(%)

ROE(%)

ROCE(%)

D/E

Div. Yld(%)

Q-Line Biotech Financials

Profit & Loss

Balance Sheet

Cash Flow

*All values are in Rs. Cr

Consolidated

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Net Sales	-	-	-	-	-
Sales	-	-	-	-	-
Less: Excise Duty	-	-	-	-	-
Operating Expenses	-	-	-	-	-
Raw Material Cost	-	-	-	-	-
Power cost	-	-	-	-	-
Employee Cost	-	-	-	-	-
Other Expenses	-	-	-	-	-
Other Manufacturing Expenses	-	-	-	-	-
Selling and administrative expenses	-	-	-	-	-
Selling Expenses	-	-	-	-	-
Miscellaneous Expenses	-	-	-	-	-
Less: Expenses Capitalised	-	-	-	-	-
Operating Profit (Excluding OI)	-	-	-	-	-
Other Income	-	-	-	-	-
Other Income Normal	-	-	-	-	-
Exceptional Items	-	-	-	-	-
Operating Profit Margin	-	-	-	-	-
EBIDTA	-	-	-	-	-
Interest	-	-	-	-	-
Depreciation	-	-	-	-	-
Profit Before Tax	-	-	-	-	-
Tax	-	-	-	-	-
Profit After Tax	-	-	-	-	-
Extra Items	-	-	-	-	-
Minority Interest	-	-	-	-	-
Share Associate	-	-	-	-	-
Other Consolidated Items	-	-	-	-	-
Net Profit	-	-	-	-	-
Equity Dividend %	-	-	-	-	-
Earnings Per Share	-	-	-	-	-
Net Profit Margin	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Equity And Liabilities	-	-	-	-	-
Shareholder's Funds	-	-	-	-	-
Share Capital	-	-	-	-	-
Share Warrants & Outstandings	-	-	-	-	-
Total Reserves	-	-	-	-	-
Reserve excluding Revaluation Reserve	-	-	-	-	-
Revaluation reserve	-	-	-	-	-
Non-Current Liabilities	-	-	-	-	-
Secured Loans	-	-	-	-	-
Unsecured Loans	-	-	-	-	-
Deferred Tax Assets / Liabilities	-	-	-	-	-
Other Long Term Liabilities	-	-	-	-	-
Rest of the Other Long Term Liabilities	-	-	-	-	-
Long Term Trade Payables	-	-	-	-	-
Long Term Provisions	-	-	-	-	-
Current Liabilities	-	-	-	-	-
Trade Payables	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Short Term Borrowings	-	-	-	-	-
Short Term Provisions	-	-	-	-	-
Assets	-	-	-	-	-
Non-Current Assets	-	-	-	-	-
Net Block	-	-	-	-	-
Gross Block	-	-	-	-	-
Less: Accumulated Depreciation	-	-	-	-	-
Less: Impairment of Assets	-	-	-	-	-
Lease Adjustment	-	-	-	-	-
Capital Work in Progress	-	-	-	-	-
Other Non Current Assets	-	-	-	-	-
Long Term Investments	-	-	-	-	-
Long Term Loans & Advances	-	-	-	-	-
Other Non Current Assets	-	-	-	-	-
Current Assets	-	-	-	-	-
Inventories	-	-	-	-	-
Account Receivables	-	-	-	-	-
Cash and Bank	-	-	-	-	-
Other Current Assets	-	-	-	-	-
Current Investments	-	-	-	-	-
Other Current Assets	-	-	-	-	-
Short Term Loans and Advances	-	-	-	-	-
Book Value	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Cash from Operations	-	-	-	-	-
Profit Before Tax	-	-	-	-	-
Adjustments	-	-	-	-	-
OCF Before Working Capital	-	-	-	-	-
Working Capital Changes	-	-	-	-	-
Taxes Paid	-	-	-	-	-
Cash from Investing Activity	-	-	-	-	-
Cash from Financing Activity	-	-	-	-	-
Net Cash Flow	-	-	-	-	-
Opening Cash & Cash Equivalents	-	-	-	-	-
Effect of FX	-	-	-	-	-
Closing Cash & Cash Equivalents	-	-	-	-	-

*All values are in Rs. Cr

Q-Line Biotech Financial Ratio

Valuation

Profitability

Efficiency

Leverage

Operational

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Book Value Per Share	-	-	-	-	-
P/B	-	-	-	-	-
P/E	-	-	-	-	-
EV/EBIDTA	-	-	-	-	-
Market Cap/Sales	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Net Profit Margin (%)	-	-	-	-	-
Gross Margin (%)	-	-	-	-	-
Operating Profit Margin (%)	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
ROE (%)	-	-	-	-	-
ROCE (%)	-	-	-	-	-
ROA (%)	-	-	-	-	-
Capital Adequacy Ratio (%)	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
D/E Ratio	-	-	-	-	-
Interest Coverage Ratio	-	-	-	-	-
Current Ratio	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Cash Conversion Cycle (Days)	-	-	-	-	-
Days Receivables (Days)	-	-	-	-	-
Inventory Days (Days)	-	-	-	-	-
Days Payables (Days)	-	-	-	-	-
Free Cash Flow to Share	-	-	-	-	-
Inventory Turnover Ratio	-	-	-	-	-
Asset Turnover Ratio	-	-	-	-	-

Q-Line Biotech Peer Comparison

Sector:

Healthcare

Industry:

Medical Equipment/Supplies/Accessories

Returns

Financials

Ratios

Name	Industry	MarketCap (Cr)	Price	1D Returns	1W Returns	1M Returns	3M Returns	6M Returns	1Y Returns	3Y Returns	5Y Returns
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	-	-	-	-	-	-	-	-
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	0.19%	-2.52%	6.98%	7.73%	1.88%	9.56%	90.14%	165.75%
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	0.66%	-1.56%	4.50%	8.39%	4.58%	1.00%	92.84%	66.12%
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	1.92%	0.44%	7.54%	8.27%	20.74%	43.05%	165.37%	231.83%
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	0.17%	0.90%	5.52%	8.55%	12.86%	16.51%	78.48%	158.60%
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	0.05%	0.83%	7.77%	8.01%	-7.02%	-4.50%	48.97%	50.84%

Name	Industry	MarketCap (Cr)	Price	Net Sales (Cr)	EBITDA (Cr)	EPS	Net Profit (Cr)	Book Value (Cr)
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	313.78	66.33	17.86	24.51	1,206.00
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	52,578.44	16,558.88	45.55	10,980.10	301.00
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	9,360.00	3,321.00	82.68	2,191.00	564.87
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	11,516.09	3,720.05	56.47	1,911.25	224.27
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	21,794.00	3,222.10	100.55	1,505.10	550.72
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	27,547.62	7,989.77	65.29	5,291.05	384.84

Name	Industry	MarketCap (Cr)	Price	PE	Industry PE	PB	Industry PB	Dividend Yield (%)	Debt To Equity
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	0	31.35	0	2.97	-	0.88
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	38.10	31.35	5.77	2.97	0.92	0.03
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	69.83	31.35	10.22	2.97	0.52	0
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	57.28	31.35	14.42	2.97	0.99	0.40
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	65.86	31.35	12.02	2.97	0.29	0.67
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	22.08	31.35	3.75	2.97	1.11	0

Q-Line Biotech Shareholding Pattern

Unable to fetch the data

Q-Line Biotech Shareholding Breakup

*All values are in %

Unable to fetch the data

Loading Financial Data...

Similar stocks

SUNPHARMA

1844.30

NSE

+3.50

(0.19%)

DIVISLAB

6797.50

NSE

+44.50

(0.66%)

TORNTPHARM

4537.80

NSE

+85.70

(1.92%)

APOLLOHOSP

8272.50

NSE

+14.00

(0.17%)

CIPLA

1418.20

NSE

+0.70

(0.05%)

Excited to Trade?

Download CapMint and start your journey now!

Engineered for the obsessed. Built for traders.

CONFIDENTLY.

Purpose-built terminals.

Zero compromise.

Built for speed.

TURBO MODESCALPER

SHIELD ORDERLIVE NOW

Plot No 1290, 2nd Floor, 17th Cross, 5th Main, Sector-7, HSR Layout, Bangalore 560102

Company

Products

Learning

Support & legal

Links:

Download Centre

Investor Charters & Grievance Reports

Most Important Terms and Conditions

Advisory to Investors

Account Opening

Filing a Complaint

SMART ODR

IRRA

NCL Client Collateral

Terms and Conditions

Disclosures

Policies

FAQs

Corporate Governance

Risk Disclosure on Derivatives

RMS Policy

Referral Terms

E-voting

About CapMint

Mintcap Brokers Private Limited
CIN – U66110KA2023PTC178706 | Registered Address: Plot No 1290, Second Floor, 17th Cross, 5th Main, Sector-7, HSR Layout, Bangalore 560102 | Tel: 080 – 49552310 | Email ID: compliance@capmint.com | SEBI registered Stock Broker: INZ000322732 | NSE Cash/F&O Member ID: 90430 | BSE Cash/F&O Member ID: 6903 | MCX Member ID: 57400 | NCDEX Member ID: 1312 | SEBI registered Depository Participant: IN-DP-806-2025 | CDSL DP ID: 12102300 | NSE Clearing Member code: M70108 | AMFI-Registered Mutual Fund Distributor: ARN-289109 (Valid upto 28-Feb-2027) | Category II Execution Only Platform : E6903

Details of Client Bank Account

Compliance Officer: Ms. Shridevi Vungarala | Email ID: compliance@capmint.com | Tel no. + 91 9035330126 | Grievance Redressal Officer (GRO) – Ms. Shikha Gupta | Email ID: Grievance@capmint.com | Tel no: 9035331595.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com > store > apps > sebiscores iOS: https://apps.apple.com > app > sebiscores

Disclaimer

Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Mutual Funds are not exchange-traded products.

Attention Investor:

(1) Prevent Unauthorized Transactions in your trading account → Update your Mobile Number/email ID with your Stock broker. Receive alerts on your Registered Mobile/email ID for all debit and other important transactions in your demat account directly from Exchanges on the same day… issued in the interest of investors. | (2) Prevent Unauthorized Transactions in your demat account → Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day… issued in the interest of investors. | (3) KYC is a one-time exercise while dealing in securities markets — once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | (4) No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
Pay 20% as upfront margin of the transaction value to trade in cash market segment.
Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Q-Line Biotech Financials

Profit & Loss

Balance Sheet

Cash Flow

*All values are in Rs. Cr

Consolidated

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Net Sales	-	-	-	-	-
Sales	-	-	-	-	-
Less: Excise Duty	-	-	-	-	-
Operating Expenses	-	-	-	-	-
Raw Material Cost	-	-	-	-	-
Power cost	-	-	-	-	-
Employee Cost	-	-	-	-	-
Other Expenses	-	-	-	-	-
Other Manufacturing Expenses	-	-	-	-	-
Selling and administrative expenses	-	-	-	-	-
Selling Expenses	-	-	-	-	-
Miscellaneous Expenses	-	-	-	-	-
Less: Expenses Capitalised	-	-	-	-	-
Operating Profit (Excluding OI)	-	-	-	-	-
Other Income	-	-	-	-	-
Other Income Normal	-	-	-	-	-
Exceptional Items	-	-	-	-	-
Operating Profit Margin	-	-	-	-	-
EBIDTA	-	-	-	-	-
Interest	-	-	-	-	-
Depreciation	-	-	-	-	-
Profit Before Tax	-	-	-	-	-
Tax	-	-	-	-	-
Profit After Tax	-	-	-	-	-
Extra Items	-	-	-	-	-
Minority Interest	-	-	-	-	-
Share Associate	-	-	-	-	-
Other Consolidated Items	-	-	-	-	-
Net Profit	-	-	-	-	-
Equity Dividend %	-	-	-	-	-
Earnings Per Share	-	-	-	-	-
Net Profit Margin	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Equity And Liabilities	-	-	-	-	-
Shareholder's Funds	-	-	-	-	-
Share Capital	-	-	-	-	-
Share Warrants & Outstandings	-	-	-	-	-
Total Reserves	-	-	-	-	-
Reserve excluding Revaluation Reserve	-	-	-	-	-
Revaluation reserve	-	-	-	-	-
Non-Current Liabilities	-	-	-	-	-
Secured Loans	-	-	-	-	-
Unsecured Loans	-	-	-	-	-
Deferred Tax Assets / Liabilities	-	-	-	-	-
Other Long Term Liabilities	-	-	-	-	-
Rest of the Other Long Term Liabilities	-	-	-	-	-
Long Term Trade Payables	-	-	-	-	-
Long Term Provisions	-	-	-	-	-
Current Liabilities	-	-	-	-	-
Trade Payables	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Short Term Borrowings	-	-	-	-	-
Short Term Provisions	-	-	-	-	-
Assets	-	-	-	-	-
Non-Current Assets	-	-	-	-	-
Net Block	-	-	-	-	-
Gross Block	-	-	-	-	-
Less: Accumulated Depreciation	-	-	-	-	-
Less: Impairment of Assets	-	-	-	-	-
Lease Adjustment	-	-	-	-	-
Capital Work in Progress	-	-	-	-	-
Other Non Current Assets	-	-	-	-	-
Long Term Investments	-	-	-	-	-
Long Term Loans & Advances	-	-	-	-	-
Other Non Current Assets	-	-	-	-	-
Current Assets	-	-	-	-	-
Inventories	-	-	-	-	-
Account Receivables	-	-	-	-	-
Cash and Bank	-	-	-	-	-
Other Current Assets	-	-	-	-	-
Current Investments	-	-	-	-	-
Other Current Assets	-	-	-	-	-
Short Term Loans and Advances	-	-	-	-	-
Book Value	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Cash from Operations	-	-	-	-	-
Profit Before Tax	-	-	-	-	-
Adjustments	-	-	-	-	-
OCF Before Working Capital	-	-	-	-	-
Working Capital Changes	-	-	-	-	-
Taxes Paid	-	-	-	-	-
Cash from Investing Activity	-	-	-	-	-
Cash from Financing Activity	-	-	-	-	-
Net Cash Flow	-	-	-	-	-
Opening Cash & Cash Equivalents	-	-	-	-	-
Effect of FX	-	-	-	-	-
Closing Cash & Cash Equivalents	-	-	-	-	-

*All values are in Rs. Cr

Q-Line Biotech Financial Ratio

Valuation

Profitability

Efficiency

Leverage

Operational

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Book Value Per Share	-	-	-	-	-
P/B	-	-	-	-	-
P/E	-	-	-	-	-
EV/EBIDTA	-	-	-	-	-
Market Cap/Sales	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Net Profit Margin (%)	-	-	-	-	-
Gross Margin (%)	-	-	-	-	-
Operating Profit Margin (%)	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
ROE (%)	-	-	-	-	-
ROCE (%)	-	-	-	-	-
ROA (%)	-	-	-	-	-
Capital Adequacy Ratio (%)	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
D/E Ratio	-	-	-	-	-
Interest Coverage Ratio	-	-	-	-	-
Current Ratio	-	-	-	-	-

Name	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Cash Conversion Cycle (Days)	-	-	-	-	-
Days Receivables (Days)	-	-	-	-	-
Inventory Days (Days)	-	-	-	-	-
Days Payables (Days)	-	-	-	-	-
Free Cash Flow to Share	-	-	-	-	-
Inventory Turnover Ratio	-	-	-	-	-
Asset Turnover Ratio	-	-	-	-	-

Q-Line Biotech Peer Comparison

Sector:

Healthcare

Industry:

Medical Equipment/Supplies/Accessories

Returns

Financials

Ratios

Name	Industry	MarketCap (Cr)	Price	1D Returns	1W Returns	1M Returns	3M Returns	6M Returns	1Y Returns	3Y Returns	5Y Returns
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	-	-	-	-	-	-	-	-
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	0.19%	-2.52%	6.98%	7.73%	1.88%	9.56%	90.14%	165.75%
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	0.66%	-1.56%	4.50%	8.39%	4.58%	1.00%	92.84%	66.12%
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	1.92%	0.44%	7.54%	8.27%	20.74%	43.05%	165.37%	231.83%
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	0.17%	0.90%	5.52%	8.55%	12.86%	16.51%	78.48%	158.60%
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	0.05%	0.83%	7.77%	8.01%	-7.02%	-4.50%	48.97%	50.84%

Name	Industry	MarketCap (Cr)	Price	Net Sales (Cr)	EBITDA (Cr)	EPS	Net Profit (Cr)	Book Value (Cr)
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	313.78	66.33	17.86	24.51	1,206.00
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	52,578.44	16,558.88	45.55	10,980.10	301.00
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	9,360.00	3,321.00	82.68	2,191.00	564.87
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	11,516.09	3,720.05	56.47	1,911.25	224.27
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	21,794.00	3,222.10	100.55	1,505.10	550.72
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	27,547.62	7,989.77	65.29	5,291.05	384.84

Name	Industry	MarketCap (Cr)	Price	PE	Industry PE	PB	Industry PB	Dividend Yield (%)	Debt To Equity
Q-Line Biotech Ltd.	Medical Equipment/Supplies/Accessories	-	0	0	31.35	0	2.97	-	0.88
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Drugs	4,42,677.30	1,844.30	38.10	31.35	5.77	2.97	0.92	0.03
Divi's Laboratories Ltd.	Pharmaceuticals & Drugs	1,80,457.58	6,797.50	69.83	31.35	10.22	2.97	0.52	0
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Drugs	1,53,684.69	4,537.80	57.28	31.35	14.42	2.97	0.99	0.40
Apollo Hospitals Enterprise Ltd.	Hospital & Healthcare Services	1,18,999.06	8,272.50	65.86	31.35	12.02	2.97	0.29	0.67
Cipla Ltd.	Pharmaceuticals & Drugs	1,14,562.27	1,418.20	22.08	31.35	3.75	2.97	1.11	0

Q-Line Biotech Shareholding Pattern

Unable to fetch the data

Q-Line Biotech Shareholding Breakup

*All values are in %

Unable to fetch the data